Skip to main content
Journal of Adolescent and Young Adult Oncology logoLink to Journal of Adolescent and Young Adult Oncology
. 2020 Jun 8;9(3):455–456. doi: 10.1089/jayao.2019.0097.correx

Correction to: Psychiatric Disorders in Adolescent and Young Adult-Onset Cancer Survivors: A Systematic Review and Meta-Analysis by De R, Zabih V, Kurdyak P, Sutradhar R, Nathan PC, McBride ML, and Gupta S. J Adolesc Young Adult Oncol. 2020;9(1):12–22. DOI: 10.1089/jayao.2019.0097

PMCID: PMC7313201  PMID: 32379518

In the February 2020 issue of Journal of Adolescent and Young Adult Oncology (vol. 9, no. 1; 12-22), the article entitled “Psychiatric Disorders in Adolescent and Young Adult-Onset Cancer Survivors: A Systematic Review and Meta-Analysis” by De et al. requires correction.

Following recent communication with Dr. Recklitis, the principal study author for one of the studies included in De et al.'s systematic review, additional information has come to the authors' attention. On page 14, this study by Recklitis et al. included patients aged 18-40 years at the time of enrollment, not at the time of diagnosis.

The original text read:

The study by Recklitis et al. was included in the systematic review but not in the meta-analysis, which reported on the prevalence of mood/affective disorders among a sample of 247, 3-year cancer survivors.17 In this population, 17.8 % of the sample had clinical mood disorders based on the DSM criteria.17 The reason for exclusion was due to the fact that an odds ratio could not be calculated from the information provided.”

The revised text now reads:

The study by Recklitis et al. was included in the systematic review but not in the meta-analysis, which reported on the prevalence of mood/affective disorders among a sample of 247, 3-year cancer survivors.17 Although patients in this study could have been aged 0-37 years at the time of cancer diagnosis, 68% of the sample was between 15-37 years at the time of their diagnosis, and thus met our inclusion criteria. In the study population, 17.8% of the sample had clinical mood disorders based on the DSM criteria.17 The reason for exclusion was due to the fact that an odds ratio could not be calculated from the information provided.

The original Table 1 is shown here:

Table 1.

Characteristics and Extracted Data from Included Studies in Systematic Review

Article Country Diagnosis years of population Type of study with comparison group Population (N and type of patients) Age range at diagnosis & study (years) Anxiety/mood-affective/substance-related disorders with tool Statistic In meta analysis?
Ahomaki et al. 2015 Finland 1975–2004 Matched retrospective cohort; compared to siblings N = 9543, ≥5 year survivors 20–34 at dx; at least 25–39 at study Mood/Affective, Anxiety and Substance-abuse disorders listed - ICD codes used for diagnoses HRs labeled as ORs in table 4 broken down by malignancy; assuming rare disease assumption, presented data were pooled Yes
Deyell et al. 2013 Canada 1970–1995 Matched retrospective cohort; compared to population N = 1280, ≥5 year survivors 15–24 at dx; at least 20–29 at time of study Mood/Affective disorders- antidepressant usage OR 1.23 (95% CI 1.07, 1.40) Yes
Dieluweit et al. 2011 Germany Cross sectional; compared to population N = 820, ≥5 year survivors 15–18 at dx; at least 20–23 at study Anxiety disorders-psychotropic medication usage OR 1.15 (95% CI 1.03, 1.27) Yes
Recklitis et al. 2016 United States Cross sectional; no direct comparison-prevalence study 247, ≥3 year survivors 18–40 at dx; at least 21–43 at study Mood/Affective disorders- DSM based test 17.8% in sample No

dx, diagnosis.

Table 1.

Characteristics and Extracted Data from Included Studies in Systematic Review

Article Country Diagnosis years of population Type of study with comparison group Population (N and type of patients) Age range at diagnosis & study (years) Anxiety/mood-affective/substance-related disorders with tool Statistic In meta analysis?
Ahomaki et al. 2015 Finland 1975–2004 Matched retrospective cohort; compared to siblings N = 9543, ≥5 year survivors 20–34 at dx; at least 25–39 at study Mood/Affective, Anxiety and Substance-abuse disorders listed - ICD codes used for diagnoses HRs labeled as ORs in table 4 broken down by malignancy; assuming rare disease assumption, presented data were pooled Yes
Deyell et al. 2013 Canada 1970–1995 Matched retrospective cohort; compared to population N = 1280, ≥5 year survivors 15–24 at dx; at least 20–29 at time of study Mood/Affective disorders- antidepressant usage OR 1.23 (95% CI 1.07, 1.40) Yes
Dieluweit et al. 2011 Germany Cross sectional; compared to population N = 820, ≥5 year survivors 15–18 at dx; at least 20–23 at study Anxiety disorders-psychotropic medication usage OR 1.15 (95% CI 1.03, 1.27) Yes
Recklitis et al. 2016 United States Cross sectional; no direct comparison-prevalence study 247, ≥3 year survivors 0–37 at dx (68% aged 15–37); 18–40 at study Mood/Affective disorders- DSM based test 17.8% in sample No

dx, diagnosis.

The corrected version is below:

Because the study by Recklitis et al. was not included in the meta-analysis, the conclusions and results remain unchanged. The online version of the article has been corrected to reflect this change. The authors sincerely apologize for this oversight.


Articles from Journal of Adolescent and Young Adult Oncology are provided here courtesy of SAGE Publications

RESOURCES